Xia J-J, Zhao S-F, Xiong L-W, Chu T-Q, Bai H, Yan B, Zhong R-B, Shao M-H, Han B-H
Shanghai Chest Hospital, Shanghai, China.
Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2805-11.
To establish and develop a reliable and simple Real-time PCR assay with high resolution melting (Real-time PCR-HRM) method for detection epidermal growth factor (EGFR) and BIM mutation of lung cancer and looking for effective targeted drugs to control lung cancer.
A total of 6858 participants (2538 cases with lung cancer and 4275 healthy controls who took part in the study by doing the physical examination in Shanghai Xuhui community) were recruited in the study. Clinical characteristics and 5 ml peripheral blood were collected from each participant, and the DNA has been extracted, which were determined the EGFR and BIM mutation by Real-time PCR-HRM. Data were recorded and Statistical analyses.
All samples completed the study. BIM deletion polymorphism was no related with age, sex, and smoking or EGFR mutation.
There were no relations among BIM deletion polymorphism, EGFR mutation or lung cancer risk. HRM is a novel procedure and provides rapid, sensitive, specific and simultaneous detection for gene mutation of cancer patients for predicting the efficacy of targeted therapy.
建立并开发一种可靠、简便的高分辨率熔解曲线实时荧光定量聚合酶链反应(Real-time PCR-HRM)方法,用于检测肺癌表皮生长因子(EGFR)和BIM突变,并寻找有效的靶向药物来控制肺癌。
本研究共纳入6858名参与者(2538例肺癌患者和4275名健康对照者,后者通过在上海徐汇社区进行体检参与研究)。收集每位参与者的临床特征及5毫升外周血,提取DNA,采用Real-time PCR-HRM法检测EGFR和BIM突变。记录数据并进行统计分析。
所有样本均完成研究。BIM缺失多态性与年龄、性别、吸烟或EGFR突变无关。
BIM缺失多态性、EGFR突变与肺癌风险之间无关联。HRM是一种新方法,可对癌症患者的基因突变进行快速、灵敏、特异且同步的检测,以预测靶向治疗的疗效。